Brevan Howard Capital Management LP Nurix Therapeutics, Inc. Transaction History
Brevan Howard Capital Management LP
- $17 Billion
- Q3 2025
A detailed history of Brevan Howard Capital Management LP transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 74,784 shares of NRIX stock, worth $957,235. This represents 0.0% of its overall portfolio holdings.
Number of Shares
74,784
Previous 62,871
18.95%
Holding current value
$957,235
Previous $716,000
3.49%
% of portfolio
0.0%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding NRIX
# of Institutions
185Shares Held
77.6MCall Options Held
99.8KPut Options Held
11.3K-
Black Rock Inc. New York, NY6.82MShares$87.3 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.06MShares$77.5 Million1.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.49MShares$57.5 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$49.7 Million0.29% of portfolio
-
Commodore Capital LP New York, NY3.78MShares$48.4 Million2.23% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $603M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...